It is thus possible that treatment with P021 during early development, by virtue of its effect on Aβ and tau pathologies, normalizes the neuroinflammation in 3xTg-AD mice, which in turn contributes to the beneficial effect of P021 on neuronal and synaptic deficits, and cognition. The gene discussed is MAPT; the disease is Alzheimer disease.